GlassScriptPhysician profile
Erin Schellenberger
NPI 1063027076
$4,437.49
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $2,417 · 2023: $1,431 · 2024: $24.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,544.09 | 2021-2023 | |
| Janssen Biotech, INC. | $421.98 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $414.01 | 2021-2023 | Entyvio |
| Genzyme Corporation | $278.31 | 2022-2023 | |
| Qol Medical, LLC | $277.85 | 2021-2023 | Sucraid |
| Pfizer INC. | $211.44 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.61 | 2022-2024 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $176.04 | 2021-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $160.37 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $139.20 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $116.10 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $112.26 | 2021-2023 | Ocaliva |
| Evoke Pharma, INC. | $84.94 | 2021-2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $55.67 | 2021-2022 | |
| Daiichi Sankyo INC. | $39.31 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $38.28 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $34.52 | 2022 | |
| Vivus LLC | $33.89 | 2021 | |
| Braintree Laboratories, INC. | $32.48 | 2022-2023 | Sutab |
| Mylan Institutional INC. | $21.08 | 2023 | Hulio |
| Gilead Sciences, INC. | $16.26 | 2022 | |
| Redhill Biopharma INC. | $13.72 | 2021 | |
| Celgene Corporation | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Schellenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.